https://orcid.org/0000-0001-7349-6770
References
- Péhourcq F. Rapid high-performance liquid chromatographic measurement of buspirone in human plasma after overdose. Biomed Chromatogr. 2004;18(9):637–640.
- Mayol RF, Adamson DS, Gammans RE, et al. Pharmacokinetics disposition of 14C-buspirone HCI after intravenous and oral dosing in man (abstr). Clin Pharmacol Ther. 1985; 37(2):21.
- Buspar (buspirone HCl, USP). Package insert. Princeton (NJ): Bristol-Myers Squibb Company; 2010.
- Mahmood I, Sahajwalla C. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet. 1999;36(4):277–287.
- Gammans RE, Mayol RF, LaBudde JA. Metabolism and disposition of buspirone. Am J Med. 1986;80(3B):41–51.
- Salazar DE, Frackiewicz EJ, Dockens R, et al. Pharmacokinetics and tolerability of buspirone during oral administration to children and adolescents with anxiety disorder and normal healthy adults. J Clin Pharmacol. 2001;41(12):1351–1358.